--- title: What Are the Risk Factors for Acute GVHD? url: "https://www.yyhmedical.com/en/faq/hsct-gvhd/acute-gvhd-risk-factors" type: FAQPage inLanguage: en-US --- # What Are the Risk Factors for Acute GVHD? > Acute GVHD risk is related to immune differences between donor and recipient and may be influenced by HLA compatibility, age, prior transfusions, and infection status. ## What Are the Risk Factors for Acute GVHD? Overview: Acute graft-versus-host disease (aGVHD) is an immune-related complication of allo-HSCT. Donor immune cells may recognize and attack normal recipient tissues, potentially injuring the skin, intestines, and liver. Not every patient develops aGVHD. Risk is influenced by several factors, including donor–recipient HLA compatibility, donor and recipient age, disease status before transplant, prior transfusions, and infections. Recognizing risk factors helps the transplant team plan prevention and monitoring. **Why are some patients more likely to develop acute GVHD?** After allo-HSCT, donor stem cells help establish a new blood-forming and immune system. At the same time, donor immune cells may recognize differences in recipient tissue antigens and mount an immune attack. Acute GVHD reflects a disruption of the immune balance between donor cells and the recipient. No single factor determines whether it will occur; clinicians evaluate multiple donor, patient, and treatment-related factors together. **Which factors can increase the risk?** - **Donor–recipient HLA compatibility** Human leukocyte antigens (HLA) are important markers of immune compatibility between donor and recipient. In general, closer HLA matching is associated with a lower risk of immune incompatibility after transplant. Greater HLA differences may make it easier for donor immune cells to recognize recipient tissues as different, potentially increasing GVHD risk. HLA testing and donor selection are therefore important before allo-HSCT. - **Donor and recipient age** Age is another consideration. Immune-cell function and activity may change with donor age, potentially influencing post-transplant immune reactions. Older recipients may also have more underlying medical conditions and reduced capacity for recovery or immune regulation. The transplant team considers these factors when evaluating complication risk. - **Transfusions before transplantation** Some patients have received multiple blood transfusions before transplant. Transfusions may expose them to immune cells or antigens from different sources, which could influence subsequent immune responses. The transplant team therefore reviews prior transfusion history as part of its overall risk assessment. - **Infection-related factors** Infections before or after transplantation may affect GVHD risk. During periods of impaired immunity, viral infections and other infections may further disturb immune balance. Infection surveillance, prevention, and appropriate management are consequently important throughout transplantation. **Is acute GVHD unavoidable?** No. Although some factors increase risk, modern transplantation includes established GVHD prevention and management measures. Clinicians can reduce risk through appropriate donor selection, thoughtful transplant-regimen design, prophylactic medications, and close post-transplant monitoring. It is also important to understand the relationship between GVHD and donor anti-leukemia immunity. Some mild GVHD may occur alongside a graft-versus-leukemia (GVL) effect, which may help lower relapse risk. The goal is not to eliminate all donor immune activity, but to control harmful reactions while preserving beneficial effects where possible. **How can acute GVHD be detected early?** Acute GVHD often appears in the early period after transplant, making close observation important. Report any new rash, skin redness or itching, persistent diarrhea or abdominal pain, nausea or vomiting, or abnormal liver tests to the transplant team. Early assessment and appropriate treatment can help prevent worsening tissue injury. **Summary** Acute GVHD risk is related to immune differences between donor and recipient and may be influenced by HLA compatibility, age, prior transfusions, and infection status. Careful assessment before transplantation, close monitoring afterward, and prompt management of changes can help reduce its impact. ## Related questions ### Q1: Does an incomplete HLA match mean I will definitely develop GVHD? No. HLA compatibility affects risk but is not the only factor. The transplant team also considers the disease, donor characteristics, and transplant regimen. ### Q2: Does acute GVHD mean my transplant has failed? No. Acute GVHD is a recognized complication, not proof of transplant failure. Mild disease may coexist with an anti-disease immune effect, but early recognition and appropriate management remain essential. ### Q3: How can the risk of acute GVHD be reduced? Measures include optimizing donor selection, planning an appropriate transplant regimen, using preventive medications, and closely monitoring the patient after transplantation. ## Content attribution (YMYL) - Author: - Medically reviewed by: - Last reviewed: - First published: > --- Original (HTML):https://www.yyhmedical.com/en/faq/hsct-gvhd/acute-gvhd-risk-factors This is a clean Markdown mirror for large language models; the original page is authoritative.